FLSM
PVLA

Frazier Life Sciences Management’s Palvella Therapeutics PVLA Stock Holding History

Frazier Life Sciences Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135M Hold
882,400
– – 2.94% 10
2026
Q1 		$110M Buy
882,400
+160,000
+22% +$16.7M 2.83% 11
2025
Q4 		$75.6M Hold
722,400
– – 2.03% 13
2025
Q3 		$45.3M Hold
722,400
– – 1.36% 19
2025
Q2 		$16.3M Buy
722,400
+32,388
+5% +$760K 0.65% 32
2025
Q1 		$19.3M Buy
690,012
+36,120
+6% +$696K 0.88% 24
2024
Q4 		$7.85M Buy
653,892
+637,950
+4,002% +$10M 0.33% 40
2024
Q3 		$267K Buy
+15,942
New +$233K 0.01% 53

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Frazier Life Sciences Management's PVLA Position: Q2 2026 in Review

Frazier Life Sciences Management held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 882,400 shares worth $135M. The position accounts for 2.94% of the portfolio, ranked #10.

Frazier Life Sciences Management first reported a position in PVLA in Q3 2024 and has held it in 8 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Frazier Life Sciences Management held 882,400 shares of Palvella Therapeutics worth $135M as of Q2 2026.
  • Frazier Life Sciences Management left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up 2.94% of Frazier Life Sciences Management's portfolio in Q2 2026, its #10 holding.
  • Frazier Life Sciences Management first reported a position in Palvella Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.